Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old

British Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2007, Pages 428-438

  Berges, A ^a   Laporte, S ^a,e   Epinat, M ^a   Zufferey, P ^a   Alamartine, E ^a   Tranchand, B ^b,c,d   Decousus, H ^a   Mismetti, P ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^e SERVICE DE NEUROLOGIE   (France)

Author keywords

Drug monitoring; Elderly; Enoxaparin; Low molecular weight heparin; NONMEM; Pharmacokinetic

Indexed keywords

CREATININE; ENOXAPARIN;

AGED; ANTICOAGULATION; ARTICLE; BAYES THEOREM; BODY WEIGHT; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMPARTMENT MODEL; COMPUTER PROGRAM; CREATININE CLEARANCE; FEMALE; GENDER; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTOR INHIBITORS; BODY WEIGHT; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 34548650727     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02920.x     Document Type: Article

References (39)

1. Zufferey P, Laporte S, Quenet S, Molliex S, Auboyer C, Decousus H, Mismetti P. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost 2003 90 : 654 61.
2. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001 88 : 913 30.
3. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients (MEDENOX). N Engl J Med 1999 341 : 793 800.
4. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000 160 : 181 8.
5. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000 355 : 1936 42.
6. Boneu B, Cadroy Y, Dol F, Caranobe C, Sie P. Pharmacocinétique des héparines. Angeiologie 1986 38 : 133 45.
7. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF. Aging and heparin related bleeding. Arch Intern Med 1996 156 : 857 60.
8. AFSSaPS. Information des prescripteurs sur l'utilisation des HBPM. J Mal Vasc 2002 27 : 231 3. (http://www.AFSSaPS.sante.fr).
9. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991 78 : 2337 43.
10. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa activity and clinical outcome in patients receiving enoxaparin low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Hemost 1989 62 : 940 4.
11. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001 27 : 519 22.
12. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovie B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991 151 : 933 8.
13. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003 121 : 12 20.
14. Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999 104 : 230 40.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999 130 : 461 70.
17. Levey AS, Greene T, Kusek JW, Beck GL, MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000 11 : 155A.
18. Schoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996 42 : 283 90.
19. Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderink GJ, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003 56 : 407 14.
20. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Clin Pharmacol 2003 56 : 96 103.
21. Green B, Greenwood M, Saltissi D, Westhuyzen J, Kluver L, Rowell J, Atherton J. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005 59 : 281 90.
22. Hulot JS, Vantelon C, Urien S, Bouzamondo A, Mahé I, Ankri A, Montalescot G, Lechat P. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 2004 26 : 305 10.
23. Hulot JS, Montalescot G, Lechat P, Collet JP, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005 77 : 542 52.
24. Kane-Gill SL, Feng Y, Bobek MB, Bies RR, Pruchnicki MC, Dasta JF. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. J Clin Pharm Ther 2005 30 : 207 13.
25. Duval V, Karlsson M. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharmaceut Res 2002 19 : 1835 40.
26. Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco : NONMEM Project Group, University of California at San Francisco 1992.
27. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982 8 : 195 222.
28. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992 20 : 511 28.
29. Pravin RJ, Jogarao Gobburu VS. A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 2005 7 : E523 31.
30. Holford N. The visual predictive check - superiority to standard diagnostic (Rorschach) plots. PAGE 2005 14 : 738 (Abstr.).
31. Tett SE, Kirkpatrick CM, Gross AS, McLachlan AJ. Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet 2003 42 : 1193 211.
32. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>7 0 years old) measured by means of Iohexol clearance, serum creatinine, serum urea and estimated clearannce. Scand J Urol Nephrol 2004 38 : 73 7.
33. Knibbe CAJ, Zuideveld KP, Aarts LPHJ, Kubs FM, Danhof M. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 2005 59 : 705 11.
34. Holford NHG. A size standard for pharmacokinetics. Clin Pharmacokinet 1996 30 : 329 32.
35. Mismetti P, Laporte-Simitsidis Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998 79 : 1162 5.
36. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol 2001 80 : 81 2.
37. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. 7th ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004 3 (Suppl. 188S 203S.
38. Mahe I, Gouin-Thibault I, Simoneau G, Drouet L, Di Castillo H, Siguret V, Bergmann JF, Pautas E. Medical elderly patients treated with prophylactic doses of enoxaparin: influence of renal function on anti-Xa activity level. Drug Aging 2007 25 : 63 71.
39. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004 110 : 392 8.